Published in Gut on December 01, 1987
The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol (1986) 1.28
Effect of transdermally administered hyoscine methobromide on nocturnal acid secretion in patients with duodenal ulcer. Br Med J (Clin Res Ed) (1982) 0.98
Transdermal scopolamine and basal acid secretion. N Engl J Med (1984) 0.96
Enprostil and ranitidine in prevention of duodenal ulcer relapse: one year double blind comparative trial. Br Med J (Clin Res Ed) (1987) 0.92
Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol (1976) 1.36
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther (1976) 1.28
Adaptation of blood pressure to continuous heavy coffee drinking in young volunteers. A double-blind crossover study. Br J Clin Pharmacol (1983) 1.10
Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther (1977) 1.08
Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther (1977) 1.07
Transdermal scopolamine and basal acid secretion. N Engl J Med (1984) 0.96
Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Br J Clin Pharmacol (1985) 0.96
Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences. Eur J Clin Pharmacol (1992) 0.91
Cyclic nucleotide phosphodiesterases of human and rat gastric mucosa. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.88
Magnesium-L-aspartate-HCl and magnesium-oxide: bioavailability in healthy volunteers. Eur J Clin Pharmacol (1991) 0.87
Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther (1989) 0.86
Effect of histamine, pentagastrin and theophylline on the production of cyclic AMP in isolated gastric tissue of the guinea pig. Naunyn Schmiedebergs Arch Pharmacol (1974) 0.86
Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl (1989) 0.84
Role of cyclic AMP in the regulation of gastric secretion in dogs and humans. Adv Cyclic Nucleotide Res (1972) 0.84
Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol (1993) 0.83
Cyclic AMP in the regulation of gastric secretion in dogs and humans. Am J Physiol (1973) 0.83
Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther (1989) 0.82
A rapid and sensitive method for the quantitation of levoprotiline in human blood and plasma. J Pharm Biomed Anal (1989) 0.80
[Pharmacokinetics and relative bioavailability of opipramol in the new INSIDON--sustained release preparation]. Fortschr Neurol Psychiatr (1998) 0.79
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J Neural Transm Suppl (1990) 0.78
Colonoscopy in the investigation of drug absorption in healthy volunteers. Gastrointest Endosc (1985) 0.78
Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol (1988) 0.78
Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. J Neural Transm Gen Sect (1994) 0.77
Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A. Eur J Clin Pharmacol (1983) 0.76
Oral tyramine pressor test and the safety of MAO inhibitor drugs. Psychopharmacology (Berl) (1987) 0.76
Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.76
Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Eur J Clin Pharmacol (1996) 0.75
Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development. Br J Clin Pharmacol (1985) 0.75
[Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations]. Fortschr Med (1991) 0.75
Glucagon-induced alterations of plasma levels of cyclic AMP and glucose in patients with liver disease. Z Gastroenterol (1984) 0.75
Clinical pharmacology of reversible monoamine oxidase-A inhibitors. Clin Neuropharmacol (1993) 0.75
Proceedings: Pharmacokinetics and protein binding of diazepam in man and different species. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.75
Interaction of alcohol and transdermally administered scopolamine. J Clin Pharmacol (1988) 0.75
The 'serotonin/norepinephrine link' beyond the beta adrenoceptor. Brain Res Mol Brain Res (1992) 0.75
[Significance of environmental medicine from the viewpoint of the medical review board of the social health insurance program]. Versicherungsmedizin (2003) 0.75
Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine. J Pharm Biomed Anal (1993) 0.75
Monoamine oxidase inhibition in healthy volunteers by CGP 11305 A, a new specific inhibitor of MAO-A. Mod Probl Pharmacopsychiatry (1983) 0.75
An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol (1998) 0.75
Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm Gen Sect (1992) 0.75
Biliary excretion studies with digoxin in man. Int J Clin Pharmacol Biopharm (1977) 0.75
Pharmacokinetic and pharmacodynamic effects of the novel benzodiazepine antagonist 2-phenylpyrazolo[4,3-c]quinolin-3(5H)-one in humans. Arzneimittelforschung (1987) 0.75
[Clinical drug trials. Part 2. Legal regulations, (EG-) guidelines, ethics commission]. Fortschr Med (1991) 0.75
[Clinical drug trials. 1: The 4 phases of clinical trials]. Fortschr Med (1991) 0.75
High-performance liquid chromatographic determination of a new pyrazoloquinoline type benzodiazepine receptor antagonist and its hydroxy metabolite. Arzneimittelforschung (1988) 0.75
Different modes of data processing and statistical testing applied to the same set of pharmaco-EEG recordings: effects on the evaluation of a selective and reversible MAO A inhibitor (brofaromine). Neuropsychobiology (1996) 0.75
The beta-adrenoceptor-coupled adenylate cyclase system in rat C6 glioma cells. Deamplification by isoproterenol and oxaprotiline. Neuropsychopharmacology (1992) 0.75
Intra-subject variability of platelet alpha 2-adrenoceptor binding sites in healthy volunteers. Methods Find Exp Clin Pharmacol (1987) 0.75
[Detection of side effects. 1: Spontaneous detection of drug risks--responsibility of the physician]. Fortschr Med (1991) 0.75
Influence of oestradiol on alpha 2-adrenoceptor binding sites on intact platelets of young male volunteers. Eur J Clin Pharmacol (1987) 0.75
Clinical pharmacology of the new COMT inhibitor CGP 28,014. Neurochem Res (1993) 0.75
Proceedings: Hepatic elimination of diazepam and its active metabolites. Arzneimittelforschung (1976) 0.75
Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers. Eur J Clin Pharmacol (1982) 0.75
Clinical pharmacology of reversible MAO-A inhibitors. Clin Neuropharmacol (1992) 0.75
Transdermally applied scopolamine does not impair psychomotor performance. Psychopharmacology (Berl) (1984) 0.75
Bioavailability of beta-acetyldigoxin after single and repeated doses of tablets and solution. Eur J Clin Pharmacol (1976) 0.75
Proceedings: Induction of drug metabolizing enzymes in man. Arzneimittelforschung (1976) 0.75
Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers. Biopharm Drug Dispos (1992) 0.75
[The new optics of the Olympus endoscope]. Z Gastroenterol (1979) 0.75
Metabolic fate of CGS 8216, a benzodiazepine receptor antagonist, in rat and in man. Psychopharmacology (Berl) (1986) 0.75
Oxaprotiline: enantioselective noradrenaline uptake inhibition indicated by intravenous amine pressor tests but not alpha 2-adrenoceptor binding to intact platelets in man. Eur J Clin Pharmacol (1993) 0.75